logo-loader
Bioasis Technologies Inc.

Full interview: Bioasis Technologies new CEO says favorable response from FDA on its xB3 therapy 'encouraging'

Bioasis Technologies Inc (OTCQB:BIOAF) (TSX.V:BTI) CEO Dr. Deborah Rathjen tells Proactive the pre-clinical biopharma group has received positive feedback from the FDA on its pre-investigational new drug (IND) application for its xB3-001 therapy for the treatment of patients with a type of breast cancer and brain metastases. Rathjen says the FDA's favorable feedback included a suggestion the company might consider the next steps of the drug development process towards entering Phase 1 trials.

Quick facts: Bioasis Technologies Inc.

Price: $0.19

Market: OTCMKTS
Market Cap: $12.31 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: The Green Organic Dutchman delivers first order to Ontario...

The Green Organic Dutchman (TSE:TGOD-US: TGODF) Director of National Sales, Ed Corcoran joined Steve Darling from Proactive Vancouver to discuss the company delivering their first order to the Ontario Cannabis Store. Corcoran telling Proactive when their product will be available in retail...

1 day, 17 hours ago

2 min read